BASAL CELL CARCINOMA
Overview
-
Commonest skin cancer
-
Most common malignancy of the eylid
-
Risk factors:
-
Fitzpatrick skin type​
-
Sun exposure
-
Advancing age
-
Immunosuppression
-
Carcinogen exposure - UV and ionising radiiation, arsenic, hydrocarbons
-
Genetic mutations
-
PTCH gene coding mutations for the sonic hedgehog signalling pathway
-
p53 tumour suppressor gene mutations​​
-
ras and fos oncogene mutations
-
Albinism
-
Naevoid basal cell syndrome (Gorlin's syndrome)
-
Autosomal dominance​
-
Chromosome 9q22.3-q31
-
Multiple basal cells, odontogenic keratocysts, palmar and plantar bits, calcifications of falx cerebri, bifid ribs, hypertelorism, broad nasal root
-
-
Xeroderma pigmentosum​
-
Autosomal recessive​
-
Impaired DNA repair mechanism
-
Intolerance to UV radiation
-
Multiple epithelial malignancies
-
-
-
Premalignant lesions​​
-
Naevus sebaceous of Jadassohn​
-
Present at birth on scalp or face​
-
Well-circumscribed, hairless, yellowish plaque that becomes verrucous and nodular at puberty
-
10-15% malignant degeneration to BCC
-
-
-
-
Originates from pluripotential epithelial cells of epidermis and hair follicles (basal keratinocystes) at the dermoepidermal junction​​​
Prognostic factors
-
Size - higher risk with increasing size
-
Site - high risk if central face, eyes, nose, lips or ears
-
Margins - higher risk with poorly defined margins
-
Histological features - high risk features include perineural or perivascular invasion
-
Failure of previous treatments - high risk if recurrent lesions
-
Immunosuppresion
Types of BCC
-
26 identified subtypes
-
Large proportion of BCCs are of mixed patterns
-
​Nodular​
-
Most common​
-
Well defined borders, flesh-coloured, pearly nodule with overlying telangeictasias
-
May be ulcerated
-
-
Superficial spreading​
-
Second most common type​
-
Confined to epidermis, no dermal invasion
-
Flat, pink, scaly patches with ulceration and crusting
-
Often mistaken for fungal infection, actinic keratosis, psoriasis or eczema
-
-
Micronodular​
-
15% of BCCs​
-
Small rounded nodules of tumour
-
-
Infiltrative​
-
7% of BCCs​
-
Opaque yellow-white colour, ill-defined
-
Tumour islands of variable size with jagged configuration
-
-
Pigmented
-
6% of BCCs​
-
Pigmentation from melanin
-
-
Morphoeic
-
2-3% of BCCs​
-
Most aggressive subtype
-
Indurated, flat, slightly elevated papule or plaque with scar-like appearance
-
High incidence of positive margins after excision
-
Treatment
-
Destructive nonsurgical
-
Imiquimod 5% (Aldara) or 5-fluorouracil cream​
-
For multiple, low-risk superficial BCC and SCC in situ​
-
-
Photodynamic therapy​
-
Good treatment for primary superficial BCC, reasonable treatment for nodular BCC​
-
5-amino-laevulinic acid or methylamino-laevulinic acid creams are used as photosensitising agents
-
-
Radiotherapy​
-
Good treatment
-
For nonsurgical candidates​
-
Delivered in fractionated doses involving orthovoltage x-rays or electron beam
-
Cure rate of primary lesions 92%
-
Risk of osteitis and skin necrosis
-
-
-
Destructive surgical​​
-
Curettage and cautery​
-
Removes visible tumour and electrodessication of residual cells​
-
For low-risk BCC
-
Based only on appearance of tumour
-
Healing by secondary intention
-
Residual tumour in 33%
-
5-year cure rate 92.3% for primary BCC, and 60% for recurrent BCC
-
-
Cryosurgery
-
Destruction of BCC using effects of extreme cold (-50-60°C) from liquid nitrogen​
-
Single or multiple freeze/thaw cycles
-
For low-risk BCC
-
5-year cure rate 99%
-
Generally heal well with minimal tissue contraction
-
-
Carbon dioxide laser​
-
Ablation using carbon dioxide laser may be effective for low-risk BCC​​
-
-
Incomplete excision
-
High-risk lesions and incompletely excised deep margins are at high risk of recurrence
-
Incompletely excised peripheral margin - 17%
-
Incompletely excised deep margin - 33%